Mylan Inc announces receipt of FDA approval for generic Parcopa ODT for Parkinson's disease

Tue. September 23, 2008; Posted: 04:29 AM

Sep 23, 2008 (M2 EQUITYBITES via COMTEX) -- SWTZY | Quote | Chart | News | PowerRating -- Mylan Inc (NYSE: MYL), a generic and specialty pharmaceutical company, said on 22 September that its subsidiary Mylan Pharmaceuticals Inc has received final approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for 10 mg/100 mg, 25 mg/100 mg and 25 mg/250 mg Carbidopa and Levodopa Orally Disintegrating Tablets (ODT), for use in the treatment of idiopathic Parkinson's disease. According to the company, Carbidopa and Levodopa ODT are the generic version of Schwarz Pharma's Parcopa ODT.

The product reported annual US sales of approximately USD7.4m for the 12 months ending 30 June 2008, for the noted strengths, according to IMS Health. Mylan said that Carbidopa and Levodopa ODT will be its first generic version tobe marketed.

Comments on this story may be sent to admin@m2.com

For full details on Ims Health Inc (RX) click here. Ims Health Inc (RX) has Short Term PowerRatings of 5. Details on Ims Health Inc (RX) Short Term PowerRatings is available at This Link.

More News: Market Updates | Stock Alerts | All Trading News | Stock Index

Archives

Feedback

Email Article Link

Close X

RELATED SITES

Please call 1-213-955-5858 ext. 1

All analyst commentary provided on TradingMarkets.com is provided for educational purposes only. The analysts and employees or affiliates of TradingMarkets.com may hold positions in the stocks or industries discussed here. This information is NOT a recommendation or solicitation to buy or sell any securities. Your use of this and all information contained on TradingMarkets.com is governed by the Terms and Conditions of Use. Please click the link to view those terms. Follow this link to read our Editorial Policy.